ALK and non-small cell lung carcinoma: The development of ALK inhibitors—from the first-generation tyrosine kinase inhibitor (TKI) crizotinib and next-generation inhibitors alectinib, ceritinib, brigatinib and lorlatinib—improved the prognosis of ALK + NSCLC patients through prolonged progression-free survival and better response rates, with enhanced drug penetration into the central nervous system [42].